毛启新, 张 敏, 郝晓甍, 张 晟, 张瑾. 铜绿假单胞菌注射液联合新辅助化疗治疗乳腺癌的临床研究*[J]. 中国肿瘤临床, 2010, 37(2): 117-120. DOI: 10.3969/j.issn.1000-8179.2010.02.014
引用本文: 毛启新, 张 敏, 郝晓甍, 张 晟, 张瑾. 铜绿假单胞菌注射液联合新辅助化疗治疗乳腺癌的临床研究*[J]. 中国肿瘤临床, 2010, 37(2): 117-120. DOI: 10.3969/j.issn.1000-8179.2010.02.014
shu
MAO Qixin, ZHANG Min, HAO Xiaomeng, ZHANG Sheng, ZHANG Jin. Clinical Effect of Neoadjuvant Chemotherapy Combined with PA-MSHA Injection on Breast Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(2): 117-120. DOI: 10.3969/j.issn.1000-8179.2010.02.014
Citation: MAO Qixin, ZHANG Min, HAO Xiaomeng, ZHANG Sheng, ZHANG Jin. Clinical Effect of Neoadjuvant Chemotherapy Combined with PA-MSHA Injection on Breast Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(2): 117-120. DOI: 10.3969/j.issn.1000-8179.2010.02.014
shu

铜绿假单胞菌注射液联合新辅助化疗治疗乳腺癌的临床研究*

Clinical Effect of Neoadjuvant Chemotherapy Combined with PA-MSHA Injection on Breast Cancer

    摘要
  • 摘要: 目的：拟评价铜绿假单胞菌注射液（PA-MSHA 菌苗）联合新辅助化疗治疗乳腺癌的有效性和安全性。方法：本研究为开放、随机、对照试验。试验组乳腺癌患者20例，对照组20例，两组采用相同的化疗方案，试验组加用铜绿假单胞菌注射液。治疗结束后评价疗效，记录患者治疗前、后的Karnofsky 评分，并在治疗前、后抽取患者静脉血，采用双抗体夹心ELISA 法检测患者的免疫功能指标（IFN-γ 、IL- 2、IL- 4、IL- 10）和其他指标（Caspase- 3、VEGF、MMP-2、MMP-9）的变化情况，观察并记录不良反应。结果：治疗后试验组的总缓解率（RR）高于对照组（P<0.05），试验组的术后病理完全缓解率（pCR ）高于对照组，但差异无统计学意义（P>0.05）；试验组治疗前和治疗后Karnofsky 评分比较，差异有统计学意义（P<0.01），试验组治疗后Karnofsky 评分显著高于对照组治疗后（P<0.01）；试验组治疗后血清IFN-γ 和IL- 2 水平高于对照组（P<0.01），IL- 4 和IL- 10水平低于对照组（P<0.05）；试验组治疗后血清Caspase- 3 浓度升高，VEGF、MMP-2 和MMP-9 血清浓度降低，治疗前、后比较差异有统计学意义（P<0.05）；对照组MMP-9 与治疗前相比显著降低（P<0.01）。 结论：铜绿假单胞菌注射液与化疗药物联合应用治疗乳腺癌可以提高总缓解率，能明显改善乳腺癌患者的细胞免疫功能，同时诱导乳腺癌细胞凋亡，降低乳腺癌细胞的侵袭能力，是乳腺癌患者理想的辅助治疗药物。

     

    Abstract: Objective: To evaluate the effect and safety of neoadjuvant chemotherapy combined with PA-MSHA injection for breast cancer patients. Methods:An open randomized controlled clinical trial was con-ducted. Fourty patients with breast cancer were randomly assigned to neoadjuvant chemotherapy group (the control group, n=20) and neoadjuvant chemotherapy combined with PA-MSHA injection group (the experi -ment group,n=20). The evaluation of therapeutic effect was carried out when the treatment was completed. Karnofsky score was recorded before and after therapy. Venous blood was drawn before and after therapy and immune function (IFN-γ, IL-2, IL- 4, and IL-10) and other indicators (Caspase-3, VEGF, MMP- 2 and MMP-9) were measured by double antibody ELISA test. Adverse effects of PA-MSHA during therapy were ob-served and recorded. Results: The overall response rate (RR) in the experiment group was significantly higher than that in the control group ( P<0.05). No significant difference was found in the pathologic complete remis -sion (pCR) between the experiment group and the control group (P>0.05). In the experimental group, pCR was significantly different before and after therapy (P<0.01). The score in the experimental group was signifi-cantly higher than that in the control group after therapy (P<0.01). With the treatment of chemotherapy and PA-MSHA injection, IFN-γ and IL-2 levels were significantly higher while IL- 4 and IL-10levels were significant -ly lower in the experiment group ( P<0.05). A significant increase in serum Caspase- 3 and a significant decrease in serum VEGF, MMP- 2 and MMP- 9 (P<0.05) after therapy were also observed in the experimental group. The level of serum MMP-9 was decreased significantly ( P<0.05) after therapy in the control group. Conclusion: Neoadjuvant chemotherapy combined with PA-MSHA injection can significantly improve the RR of breast cancer patients, enhance their cellular immune function, induce the apoptosis and restrain the metastasis of breast cancer cells. The PA-MSHA has been proved to be an ideal supplementary therapy for breast cancer.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回